INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGXGlobeNewsWire • 08/17/25
How Argenx's 'Blowout' Quarter Sparked A Blazing 31% Monthlong RunInvestors Business Daily • 08/15/25
argenx and Tennis Legend Monica Seles Team Up to Raise Awareness of Myasthenia GravisGlobeNewsWire • 08/12/25
argenx Reports Half Year 2025 Financial Results and Provides Second Quarter Business UpdateGlobeNewsWire • 07/31/25
argenx to Report Half Year 2025 Financial Results and Second Quarter Business Update on July 31, 2025GlobeNewsWire • 07/24/25
argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating PolyneuropathyGlobeNewsWire • 06/20/25
argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren's DiseaseGlobeNewsWire • 06/10/25
Argenx Beats Sales Expectations — But Not By Enough — And Shares TumbleInvestors Business Daily • 05/08/25
argenx Reports First Quarter 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 05/08/25
argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025GlobeNewsWire • 05/01/25
argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)GlobeNewsWire • 04/28/25